Facet Biotech Corporation
17Patents
15Active
17Granted
45Portfolio score
Filing activity: Nov 5, 2004 → Aug 12, 2009 · 15 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7592004B2 | Stable lyophilized pharmaceutical formulation of IgG antibodies | Human Necessities | 35 | Expired |
| US7709610B2 | Therapeutic use of anti-CS1 antibodies | Chemistry; Metallurgy | 27 | Active |
| US7662384B2 | Use of anti-α5β1 antibodies to inhibit cancer cell proliferation | Chemistry; Metallurgy | 16 | Expired |
| US7666419B2 | Anti-CCR5 antibody | Chemistry; Metallurgy | 12 | Active |
| US7732195B2 | Tethered vectors for cell surface immunoglobulin display | Chemistry; Metallurgy | 9 | Active |
| US7732570B2 | Alteration of Fc-fusion protein serum half-lives by mutagenesis | Chemistry; Metallurgy | 7 | Active |
| US7807163B2 | Antibodies against GPR64 and uses thereof | Chemistry; Metallurgy | 6 | Active |
| US7842293B2 | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma | Human Necessities | 4 | Active |
| US7674883B2 | Antibodies against cancer antigen TMEFF2 and uses thereof | Chemistry; Metallurgy | 3 | Active |
| US7824678B2 | Antibodies against cancer antigen TMEFF2 and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US7785816B2 | Antibodies against cancer antigen TMEFF2 and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US7851600B2 | Anti-CCR5 antibody | Chemistry; Metallurgy | 1 | Active |
| US8298530B2 | Stable lyophilized pharmaceutical formulation of IgG antibodies | Human Necessities | 0 | Active |
| US7547544B2 | Antibodies against GPR64 and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US7914789B2 | HEMCM42 antibodies | Human Necessities | 0 | Active |
| US7879987B2 | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis | Chemistry; Metallurgy | 0 | Active |
| US7776585B2 | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.